Teva CEO: Our supply chain puts us in a strong position

Financial Performance - Teva Pharmaceuticals reported an earnings beat in Q2 and raised revenue guidance for the year end [1] - Teva's innovative drugs grew by 27% this quarter [3] - AJOVY grew at 31%, AUSTEDO is up 120%, and AJOVY is up 22% in the US [7] - AUSTEDO is expected to achieve $2 billion in sales this year and is growing at 22% in the US [9] - The company is focused on paying down debt, growing the top line, and increasing profitability to achieve investment grade [11][12] - Earnings per share are up [12] Market Dynamics and Pipeline - Tariffs could put pressure on drug makers and their manufacturing overseas [1] - Approximately 43% of branded drugs sold in the US come from Europe, and about 18% of generics [2] - Teva has limited exposure to tariffs emerging from China and India due to its supply chain [4] - Teva is transforming from a pure play generics player to a biopharma player [13] - Teva plans to file lanzipene with the FDA towards the end of this year, bring a treatment for asthma to market in 2027, and a treatment for oscillitis and Crohn's disease to market in 2028-2029 [15]